Three questions on… desogestrel and panic attacks

UMC’s Research pharmacist Sarah Watson explains the significance of a recently published signal that links contraceptive drug desogestrel to panic attacks.

---

---

A guide to reporting disproportionality analyses – New podcast episode

The READUS-PV statement is the first-ever guide for reports of disproportionality analyses that are replicable, reliable, and reproducible.

---

---

vigiGroup in action – new method identifies groups of related reports

See how UMC’s new clustering algorithm identifies groups of related reports in our new explainer animation.

---

---

When medicines change our behaviour – New podcast out now

Adverse effects to medicines are not just physical in nature, but can manifest as behavioural side-effects too. How do we diagnose and treat these complex ADRs?

---

---

The paediatric screening – a clinician’s perspective

---

---

The ABCs of pharmacovigilance: Egypt’s signal management approach in action

Egypt's swift detection of vincristine-associated necrotising infections demonstrates how effective pharmacovigilance can identify risks and protect patients globally.

---

---

UMC science gets personal

The Research corner film series puts UMC pharmacovigilance scientists in the spotlight as they discuss their research and its implications for pharmacovigilance science.

---

---

Digging deeper into Montelukast and nightmares

There is much to be gained from using VigiBase to further explore known adverse reactions to drugs, as some may be having more of an impact on patients than first thought.

---

---

How VigiFlow is helping to keep the wheel of pharmacovigilance turning in South Africa

South Africa’s pharmacovigilance system has been evolving for over a decade with UMC’s data management system supporting them every step of the way.

---

---

Towards precision pharmacovigilance

Using the techniques of precision medicine, individual risk factors, including genetics, can be used to predict which patients will most likely experience an adverse drug reaction.

---

---